Every material Form 8-K Pulmonx Corp has filed with the SEC since April 29, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Pulmonx reported third-quarter 2026 revenue of $22.8 million, up 6% from a year earlier, and a net loss of $8.4 million, or $0.19 per share, compared with a $14.0 million loss, or $0.34 per share, a year earlier. The company kept its full-year 2026 revenue outlook at $90 million to $92 million, and it expects cash, cash equivalents, and marketable securities to decline by about $22 million for the year.
Q3 2026 revenue was $22.8 million, up from $21.5 million; U.S. revenue rose 7% and international revenue rose 5%, with international growth tempered by no sales to its China distributor
Net loss was $8.4 million, or $0.19 per share, versus $14.0 million, or $0.34 per share, in Q3 2025; operating expenses fell 18% to $24.9 million
Full-year 2026 revenue guidance of $90 million to $92 million was unchanged; the company expects gross margin of about 77% and operating expenses of $108 million to $109 million
Nine-month revenue was $66.2 million, down 2.5% from $67.9 million a year earlier
Pulmonx reported second-quarter 2026 revenue of $22.8 million, down 5% from a year earlier, as international sales fell because of a lack of sales into China while its registration certificate was awaited. Net loss narrowed to $10.1 million, or $0.24 per share, from $15.2 million, or $0.38 per share, as operating expenses fell 16%. The company kept its full-year 2026 revenue outlook of $90 million to $92 million.
Q2 2026 worldwide revenue was $22.8 million, down 5% from $23.9 million; U.S. revenue was $14.2 million, down 4%.
Gross margin rose to 78% from 72%; the company now expects full-year 2026 gross margin of approximately 76%.
Net loss was $10.1 million ($0.24 per share) versus $15.2 million ($0.38 per share) a year earlier; adjusted EBITDA loss was $5.1 million, down 39%.
Full-year 2026 revenue outlook of $90 million to $92 million was unchanged; total operating expense outlook is $109 million to $111 million.
Pulmonx reported first-quarter 2026 revenue of $20.6 million, down 9% from $22.5 million a year earlier, driven by a lack of China sales while it awaits renewal of its registration certificate. The net loss narrowed to $13.7 million, or $0.33 per share, from $14.4 million, or $0.36 per share, and the company kept its full-year 2026 revenue outlook of $90 million to $92 million unchanged.
Worldwide revenue was $20.6 million, down 9% year over year and down 12% on a constant currency basis.
International revenue fell 12% to $7.3 million, while international revenue excluding China grew 22%.
Gross margin rose to 78% from 73%, and the net loss narrowed to $13.7 million, or $0.33 per share.
Full-year 2026 revenue guidance of $90 million to $92 million was reiterated, and cash and equivalents were $61.6 million as of March 31, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Pulmonx Corp filing is on SEC EDGAR ↗. 8-K briefs of other companies →